Navigation Links
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
Date:8/7/2014

ollaboration agreement with Sanofi Pasteur. KaloBios has stated that it intends to seek a partner with a focus on infectious disease, hospital pharmaceuticals, or cystic fibrosis who can accelerate and financially support the future development of KB001-A."We are very excited about the recent progress we have made on our programs," said Nestor A. Molfino, MD, MSc, Chief Medical Officer of KaloBios. "Completing enrollment in our Phase 2 KB001-A study in CF patients in a timeframe that will potentially allow us to report out top-line data in early 2015 was a major achievement for the company. At the same time, completing enrollment in the KB004 Phase 1 dose escalation study sets the stage for us to initiate enrollment in the high-dose cohorts in the Phase 2 efficacy-seeking portion of our KB004 study in the second half of 2014."

Key Anticipated Milestones for 2014-20152H 2014:Full enrollment of the KB001-A CF Phase 2 study (completed in July 2014)Q4 2014:

Completion of enrollment in at least one indication in the Phase 2 expansion portion of our KB004 study in hematologic malignanciesQ1 2015:

Top line KB001-A CF Phase 2 study resultsSecond Quarter 2014 Financial Results
Net loss for the three months ended June 30, 2014 was $9.8 million or $0.30 per common share, as compared to $11.8 million or $0.49 per common share for the same period in 2013. 

No contract revenue was reported for the second quarter of 2014 as compared to $15,000 reported in the same period in 2013. The decrease in contract revenues was due to the completion of all substantive performance obligations related to research support activities under our agreement with Sanofi Pasteur.

Research and development (R&D) expenses were $6.7 million for the three months ended June 30, 2014 as compared to $9.6 million for the same period in 2013. The decrease in R&D expense was primarily due to decreased clinical trial activity compared with the prior period
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. KaloBios Provides Update on KB001-A Partnership and Clinical Status
2. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
3. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
4. KaloBios Elects Laurie Smaldone Alsup, M.D. to Board
5. KaloBios to Present at Leerink Swann Rare Disease Roundtable
6. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
7. Herb C. Cross to Join KaloBios as Chief Financial Officer
8. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
9. KaloBios to Present at Stifel Healthcare Conference 2013
10. KaloBios Reports First Quarter 2013 Financial Results
11. KaloBios to Present at Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... (Nasdaq: YDNT ) today announced that it will ... on-demand web cast conference call on Thursday, October 21, 2010 ... the call will be available through InterCall at http://tinyurl.com/Quarter32010 ... available through the Company,s website, www.ydnt.com . ...
... one of the world,s largest and most sophisticated pharmacies ... (D-Nev.), today said innovative companies such as Medco Health ... bright future for a sustainable healthcare system for America ... Nevada by providing employment opportunities for skilled healthcare professionals. ...
Cached Medicine Technology:Young Innovations, Inc. Provides 3rd Quarter Conference Call Details 2Sen. Harry Reid to Medco Employees: Technology and Innovation Integral to Sustainable Healthcare Reform and Nevada's Future 2Sen. Harry Reid to Medco Employees: Technology and Innovation Integral to Sustainable Healthcare Reform and Nevada's Future 3
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce that ... at North Carolina State’s College of Veterinary Medicine has ... for Distinguished Volunteer Service—the organization’s highest award. , ... volunteer experts to direct its work to improve the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... US-based Redux Beverages said it would be marketing. Well, only it was ... drink. ,In September last year it announced the launch ... illegal drug. ,Jamey Kirby, the drink's inventor, said the name ... session at 1 o'clock in the morning. ,"It's an ...
... Cedars-Sinai Medical Center in Los Angeles have reported that they ... who had died and retransplanted it in another recipient. ... has been done with a transplanted heart, said Dr. Lawrence ... program. Even with other organs, repeat transplantation is very rare. ...
... nerve cells signal to one another could rewrite the textbooks ... Weill Cornell Medical College and Yale University. ,Their ... Science, suggests that a key cellular enzyme called dynamin 1 ... previously assumed. ,Dynamin has long been a focus ...
... Children's Research Hospital have discovered inherited variations in certain ... (ALL) susceptible to the toxic side effects caused by ... polymorphisms, occur in specific genes known to influence pharmacodynamics ... drug is needed to have its intended effect). ...
... blood pressure and additional risk factors for heart ... rather than two , if their current treatment ... pressure-lowering medication amlodipine, researchers reported at the American ... Care and Outcomes Research in Cardiovascular Disease and ...
... mother's love is something we all treasure.; Same is the case ... Delhi . ,She has something special planned for her ... wished to be with her mother on Sunday, which is now ... her spirits down. Last time when I was in Delhi, I ...
Cached Medicine News:Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 2Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 3Health News:Transplanted Heart Goes to a Second Recipient in a Rare Surgery 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 3Health News:Inherited Genes Linked to Toxicity of Leukemia Therapy 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: